Milveterol

DB05043InvestigationalSmall molecule

GSK159797 ('797) is an inhaled, longer-acting Beta2 agonist developed for the treatment of respiratory disease such as asthma and COPD.

Mechanism: GSK159797 is a longer-acting beta-2 adrenoceptor agonist. It acts on the beta2-adrenergic receptor, thereby causing smooth muscle relaxation resulting in dilation of bronchial passages.
Curator reviewed
Primary indication: Investigated for use/treatment in asthma and chronic obstructive pulmonary disease (COPD).Curator reviewed
Code names: GSK159797

Resolves to

Compound

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Milveterol, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.